MedicaidPrior AuthMedium impact
Elitek® (rasburicase) (New)
Humana·LA · Oncology, Hematology, Pharmacy·Medicaid
Effective date
Jun 1, 2026
We identified it
Jun 24, 2026
Summary
Humana has established a new prior authorization policy for Elitek (rasburicase) for Louisiana Medicaid members effective June 1, 2026. The policy requires prior authorization for patients with leukemia, lymphoma, or solid tumors receiving chemotherapy expected to cause tumor lysis syndrome, with specific exclusions for G6PD deficiency and previous adverse reactions.
Action Required
Before June 1, 2026: Billing team must update prior authorization requirements for Elitek (rasburicase) for Louisiana Medicaid patients. Ensure providers document diagnosis of leukemia, lymphoma, or solid tumor malignancy and confirm patients are receiving anti-cancer chemotherapy expected to cause tumor lysis syndrome. Verify patients do not have G6PD deficiency or history of adverse reactions to rasburicase before submitting prior auth requests. Claims will be denied without proper prior authorization.